Anggaya, Riley .

HRN: 25-65-73  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/29/2025
OXACILLIN 500MG (VIAL)
01/29/2025
02/04/2025
IV
300mg
Q6h
Cellulitis
Waiting Final Action 
01/29/2025
MUPIROCIN 2%, 15G (TUBE)
01/29/2025
02/04/2025
TOPICAL
Thin Layer
TID
Cellulitis
Waiting Final Action 
04/24/2025
CEFUROXIME 750MG (VIAL)
04/24/2025
05/01/2025
IV
350mg
Q8h
PCAP C
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: